CareDx’s (CDNA) “Neutral” Rating Reiterated at HC Wainwright

CareDx (NASDAQ:CDNA)‘s stock had its “neutral” rating reiterated by analysts at HC Wainwright in a research report issued on Tuesday, Benzinga reports.

Other equities analysts have also issued reports about the company. Wells Fargo & Company started coverage on CareDx in a report on Tuesday, August 27th. They set an “underweight” rating and a $28.00 target price on the stock. StockNews.com upgraded CareDx from a “hold” rating to a “buy” rating in a report on Thursday, October 17th. The Goldman Sachs Group increased their price target on CareDx from $26.00 to $35.00 and gave the company a “buy” rating in a report on Wednesday, October 16th. Craig Hallum boosted their price objective on shares of CareDx from $22.00 to $32.00 and gave the stock a “buy” rating in a research note on Thursday, August 1st. Finally, BTIG Research upgraded shares of CareDx from a “neutral” rating to a “buy” rating and set a $40.00 target price on the stock in a report on Monday, August 19th. One research analyst has rated the stock with a sell rating, two have issued a hold rating and five have given a buy rating to the company’s stock. According to data from MarketBeat, the stock has a consensus rating of “Moderate Buy” and an average target price of $30.60.

CareDx Trading Down 0.1 %

Shares of NASDAQ:CDNA opened at $23.11 on Tuesday. The business has a fifty day simple moving average of $29.36 and a 200 day simple moving average of $19.99. CareDx has a 1 year low of $4.80 and a 1 year high of $34.84. The firm has a market cap of $1.20 billion, a price-to-earnings ratio of -6.76 and a beta of 1.77.

CareDx (NASDAQ:CDNA) last announced its quarterly earnings results on Wednesday, July 31st. The company reported ($0.03) EPS for the quarter, beating the consensus estimate of ($0.40) by $0.37. The business had revenue of $92.27 million during the quarter, compared to analysts’ expectations of $67.20 million. CareDx had a negative return on equity of 53.65% and a negative net margin of 53.73%. On average, sell-side analysts forecast that CareDx will post -0.84 EPS for the current year.

Insider Buying and Selling

In other CareDx news, insider Alexander L. Johnson sold 21,557 shares of the stock in a transaction on Wednesday, August 21st. The shares were sold at an average price of $32.58, for a total value of $702,327.06. Following the completion of the sale, the insider now directly owns 284,983 shares of the company’s stock, valued at $9,284,746.14. This represents a 0.00 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. In other CareDx news, Director Peter Maag sold 35,552 shares of the company’s stock in a transaction that occurred on Tuesday, August 20th. The stock was sold at an average price of $33.04, for a total value of $1,174,638.08. Following the completion of the transaction, the director now owns 330,024 shares of the company’s stock, valued at $10,903,992.96. This represents a 0.00 % decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available at this link. Also, insider Alexander L. Johnson sold 21,557 shares of the company’s stock in a transaction on Wednesday, August 21st. The shares were sold at an average price of $32.58, for a total value of $702,327.06. Following the completion of the transaction, the insider now owns 284,983 shares of the company’s stock, valued at $9,284,746.14. The trade was a 0.00 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 91,340 shares of company stock valued at $3,025,415. 4.20% of the stock is owned by company insiders.

Institutional Investors Weigh In On CareDx

Several institutional investors and hedge funds have recently bought and sold shares of CDNA. GAMMA Investing LLC boosted its holdings in CareDx by 1,021.8% during the second quarter. GAMMA Investing LLC now owns 2,210 shares of the company’s stock valued at $34,000 after purchasing an additional 2,013 shares in the last quarter. Plato Investment Management Ltd acquired a new position in CareDx during the 2nd quarter worth $62,000. nVerses Capital LLC lifted its holdings in CareDx by 175.0% during the 3rd quarter. nVerses Capital LLC now owns 3,300 shares of the company’s stock worth $103,000 after buying an additional 2,100 shares in the last quarter. Meeder Asset Management Inc. acquired a new stake in shares of CareDx in the 2nd quarter valued at $142,000. Finally, Allspring Global Investments Holdings LLC increased its stake in shares of CareDx by 10,267.2% in the 1st quarter. Allspring Global Investments Holdings LLC now owns 18,661 shares of the company’s stock valued at $198,000 after buying an additional 18,481 shares during the period.

About CareDx

CareDx, Inc engages in the discovery, development, and commercialization of diagnostic solutions for transplant patients and caregivers in the United States and internationally. It also provides AlloSure Kidney, a donor-derived cell-free DNA (dd-cfDNA) solution for kidney transplant patients; AlloMap Heart, a gene expression solution for heart transplant patients; AlloSure Heart, a dd-cfDNA solution for heart transplant patients; and AlloSure Lung, a dd-cfDNA solution for lung transplant patients.